Comparative efficacy of different chemotherapies for non-Hodgkin lymphoma: a network-meta analysis

Abstract

This network meta-analysis (NMA) was conducted to integrate different chemotherapeutic regimens for non-Hodgkin lymphoma (NHL) patients. Overall survival (OS) and complete remission (CR) were considered as main outcome indicators to evaluate the efficacy of NHL chemotherapies. OS and CR data were extracted from included studies and represented by hazard ratio and odds ratio separately. Network structure and forest plots were further included to visually present the relative efficacy among different regimens. A total of 14 qualified publications with 4,167 patients were included. In OS results, no significant difference was observed from the 1-year OS. For 2-year, 3-year and 5-year OS, patients treated by CNOP exhibited the least favorable results. Moreover, significant advantages of R-CHOP treatment over CHOP and VMP were recognized in view of 3-year OS. In respect of CR, R-HDS presented significantly better outcomes than CNOP and VMP, and no significant difference was identified when compared to CHOP in forest plot. ProMACE-CytaBOM and R-HDS possessed the compelling cumulative ranking probability in OS or CR, indicating their competitive performance in NHL treatment while R-CHOP and I-CHOP yielded desirable in terms of long-term survival and short-term survival, respectively. To conclude, ProMACE-CytaBOM, I-CHOP, R-HDS and R-CHOP were recommended to go through further evaluation to confirm their superiority in NHL treatment. CNOP and VMP were discouraged after comprehensively analyzing OS and CR from NMA results.

Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neuropathy among patients with chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of data from 29 countries between 2000 and 2024

“…Specifically, non-small cell lung cancer is commonly treated with platinum-based chemotherapy regimens, such as cisplatin and carboplatin, which are well known for their high neurotoxicity profiles 30. In contrast, lymphoma treatments may involve less neurotoxic regimens, such as anthracyclines or targeted therapies,31 32 which may contribute to the lower prevalence of chronic painful CIPN.…”

Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neuropathy among patients with chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of data from 29 countries between 2000 and 2024

“…Specifically, non-small cell lung cancer is commonly treated with platinum-based chemotherapy regimens, such as cisplatin and carboplatin, which are well known for their high neurotoxicity profiles 30. In contrast, lymphoma treatments may involve less neurotoxic regimens, such as anthracyclines or targeted therapies,31 32 which may contribute to the lower prevalence of chronic painful CIPN.…”

Primary pleural lymphoma of T cell origin in a paediatric patient with a focus on radiological findings – a case report and review of literature

“…The majority of cases presented to date have been treated with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), which is the standard treatment for non-Hodgkin's B-cell lymphoma. This regimen has proven to be of beneficence for cases with diffuse large B-cell lymphomas, but has also shown considerable mortality, especially because of neutropaenic fever [4] (Table 1). In this case report, we discuss a four-year-old Azeri boy who was diagnosed with primary pleural lymphoma.…”

Current Aspects of Non Hodgkin Lymphoma (NHL) In Bangladesh: A Mini Review

“…However, its CR performance was astounding. In addition, R-CHOP, the standard gold treatment for DLBCL according to the International Prognostic Index, ranked first in 3-year and 5-year overall survival, indicating its value in achieving a more excellent long-term prognosis than all other types of NHL, while I-CHOP was effective in shortterm survival outcomes [20].…”

Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neuropathy among patients with chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of data from 29 countries between 2000 and 2024

“…Specifically, non-small cell lung cancer is commonly treated with platinum-based chemotherapy regimens, such as cisplatin and carboplatin, which are well known for their high neurotoxicity profiles 30. In contrast, lymphoma treatments may involve less neurotoxic regimens, such as anthracyclines or targeted therapies,31 32 which may contribute to the lower prevalence of chronic painful CIPN.…”

Primary pleural lymphoma of T cell origin in a paediatric patient with a focus on radiological findings – a case report and review of literature

“…The majority of cases presented to date have been treated with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), which is the standard treatment for non-Hodgkin's B-cell lymphoma. This regimen has proven to be of beneficence for cases with diffuse large B-cell lymphomas, but has also shown considerable mortality, especially because of neutropaenic fever [4] (Table 1). In this case report, we discuss a four-year-old Azeri boy who was diagnosed with primary pleural lymphoma.…”

Current Aspects of Non Hodgkin Lymphoma (NHL) In Bangladesh: A Mini Review

“…However, its CR performance was astounding. In addition, R-CHOP, the standard gold treatment for DLBCL according to the International Prognostic Index, ranked first in 3-year and 5-year overall survival, indicating its value in achieving a more excellent long-term prognosis than all other types of NHL, while I-CHOP was effective in shortterm survival outcomes [20].…”

Global estimates of prevalence of chronic painful neuropathy and moderate-to-severe neuropathy among patients with chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of data from 29 countries between 2000 and 2024

“…Specifically, non-small cell lung cancer is commonly treated with platinum-based chemotherapy regimens, such as cisplatin and carboplatin, which are well known for their high neurotoxicity profiles 30. In contrast, lymphoma treatments may involve less neurotoxic regimens, such as anthracyclines or targeted therapies,31 32 which may contribute to the lower prevalence of chronic painful CIPN.…”

Primary pleural lymphoma of T cell origin in a paediatric patient with a focus on radiological findings – a case report and review of literature

“…The majority of cases presented to date have been treated with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), which is the standard treatment for non-Hodgkin's B-cell lymphoma. This regimen has proven to be of beneficence for cases with diffuse large B-cell lymphomas, but has also shown considerable mortality, especially because of neutropaenic fever [4] (Table 1). In this case report, we discuss a four-year-old Azeri boy who was diagnosed with primary pleural lymphoma.…”

Current Aspects of Non Hodgkin Lymphoma (NHL) In Bangladesh: A Mini Review

“…However, its CR performance was astounding. In addition, R-CHOP, the standard gold treatment for DLBCL according to the International Prognostic Index, ranked first in 3-year and 5-year overall survival, indicating its value in achieving a more excellent long-term prognosis than all other types of NHL, while I-CHOP was effective in shortterm survival outcomes [20].…”